Elizabethkingia meningoseptica Outbreak in NICU: An Observational Study on a Debilitating Neuroinfection in Neonates.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
medline:
15
12
2023
pubmed:
15
12
2023
entrez:
15
12
2023
Statut:
ppublish
Résumé
Elizabethkingia meningoseptica is an emerging nosocomial pathogen implicated in neonatal sepsis with high mortality and morbidities. However, there is very limited data regarding the characteristics as well as outcomes following this infection, particularly in developing countries. We conducted a retrospective observational study of all infants with culture-positive Elizabethkingia sepsis as part of an outbreak, to study their clinical and epidemiological characteristics, as well as their antimicrobial susceptibility patterns, using a structured proforma from the neonatal intensive care unit database. Analysis was done using descriptive statistics and predictors of mortality and hydrocephalus were also identified. Of the 21 neonates enrolled, 9 (42.9%) were male, with a mean gestational age and birth weight of 31.7 ± 3.4 weeks and 1320 ± 364 g, respectively. The median (interquartile range) age of onset of illness was 7 (5-12) days. The overall mortality rate was 23.8%, and among survivors, 50% had neurologic complications requiring intervention. Vancomycin and ciprofloxacin were the most used antibiotics for treatment in our series, with a median duration of 26 (17-38) days. On univariate analysis, shock at presentation was significantly associated with increased mortality (P = 0.04) while, seizures (P = 0.04) and elevated cerebrospinal fluid protein levels (P = 0 .01) at onset of illness predicted progressive hydrocephalus in surviving neonates. E. meningoseptica sepsis is associated with high morbidity and mortality. Early diagnosis and prompt initiation of appropriate antibiotics are critical for improving survival and neurodevelopmental outcomes. Though isolation of the organism by environmental surveillance is always not possible, with proper infection control measures, the infection can be controlled.
Sections du résumé
BACKGROUND
BACKGROUND
Elizabethkingia meningoseptica is an emerging nosocomial pathogen implicated in neonatal sepsis with high mortality and morbidities. However, there is very limited data regarding the characteristics as well as outcomes following this infection, particularly in developing countries.
METHODS
METHODS
We conducted a retrospective observational study of all infants with culture-positive Elizabethkingia sepsis as part of an outbreak, to study their clinical and epidemiological characteristics, as well as their antimicrobial susceptibility patterns, using a structured proforma from the neonatal intensive care unit database. Analysis was done using descriptive statistics and predictors of mortality and hydrocephalus were also identified.
RESULTS
RESULTS
Of the 21 neonates enrolled, 9 (42.9%) were male, with a mean gestational age and birth weight of 31.7 ± 3.4 weeks and 1320 ± 364 g, respectively. The median (interquartile range) age of onset of illness was 7 (5-12) days. The overall mortality rate was 23.8%, and among survivors, 50% had neurologic complications requiring intervention. Vancomycin and ciprofloxacin were the most used antibiotics for treatment in our series, with a median duration of 26 (17-38) days. On univariate analysis, shock at presentation was significantly associated with increased mortality (P = 0.04) while, seizures (P = 0.04) and elevated cerebrospinal fluid protein levels (P = 0 .01) at onset of illness predicted progressive hydrocephalus in surviving neonates.
CONCLUSION
CONCLUSIONS
E. meningoseptica sepsis is associated with high morbidity and mortality. Early diagnosis and prompt initiation of appropriate antibiotics are critical for improving survival and neurodevelopmental outcomes. Though isolation of the organism by environmental surveillance is always not possible, with proper infection control measures, the infection can be controlled.
Identifiants
pubmed: 38100733
doi: 10.1097/INF.0000000000004117
pii: 00006454-202401000-00012
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
63-68Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Sarma S, Kumar N, Jha A, et al. Elizabethkingia meningosepticum: an emerging cause of septicemia in critically III patients. J Lab Physicians. 2011;3:62–63.
Ozkalay N, Anil M, Agus N, et al. Community-acquired meningitis and sepsis caused by Chryseobacterium meningosepticum in a patient diagnosed with thalassemia major. J Clin Microbiol. 2006;44:3037–3039.
Bloch KC, Nadarajah R, Jacobs R. Chryseobacterium meningosepticum: an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review. Medicine (Baltim). 1997;76:30–41.
Dziuban EJ, Franks JL, So M, et al. Elizabethkingia in children: a comprehensive review of symptomatic cases reported from 1944 to 2017. Clin Infect Dis. 2018;67:144–149.
Issack MI, Neetoo Y. An outbreak of Elizabethkingia meningoseptica neonatal meningitis in Mauritius. J Infect Dev Ctries. 2011;5:834–839.
Shailaja VV, Reddy AK, Alimelu M, et al. Neonatal meningitis by multidrug resistant Elizabethkingia meningosepticum identified by 16S ribosomal RNA gene sequencing. Int J Pediatr. 2014;2014:918907.
Kumar C, Sastry AS, Plakkal N. Neonatal sepsis and meningitis caused by Elizabethkingia. Indian J Pediatr. 2021;88:598–598.
Joshi P, Shah B, Joshi V, et al. Treatment of Elizabethkingia meningoseptica neonatal meningitis with combination systemic and intraventricular therapy. Indian J Pediatr. 2019;86:379–381.
Anil AM, B A, Sastry AS. Clinical profile and outcome of neonates with Elizabethkingia sepsis. Indian J Pediatr. 2023;90:612–614.
Abhishek KS, Kombade SP, Gupta N, et al. Case Series and mini-review on Elizabethkingia meningoseptica, a high alert organism causing meningitis in premature neonates from a tertiary care hospital of Western Rajasthan. Infect Disord Drug Targets. 2021;21:e160921189884.
National Neonatology Forum India. Evidence Based Clinical PRACTISE guideline. 1st ed. Chandrika Press; 2010.
Prasad R, Rameshbabu M, Sourabh D, et al. NNF Clinical Practice Guidelines. Diagnosis and Management of Neonatal Sepsis. 2021 [cited 2023 Mar 2]
Limbrick DD, de Vries LS. New insights into the management of post-hemorrhagic hydrocephalus. Semin Perinatol. 2022;46:151597.
Hammersmith Neonatal and Infant Neurological Examinations. Mac Keith Press. [cited 2023 Mar 1]. Available at: https://www.mackeith.co.uk/hammersmith-neurological-examinations/
Ghafur A, Vidyalakshmi PR, Priyadarshini K, et al. Elizabethkingia meningoseptica bacteremia in immunocompromised hosts: the first case series from India. South Asian J Cancer. 2013;2:211–215.
Ratnamani MS, Rao R. Elizabethkingia meningoseptica: emerging nosocomial pathogen in bedside hemodialysis patients. Indian J Crit Care Med. 2013;17:304–307.
Govindaswamy A, Bajpai V, Trikha V, et al. Multidrug resistant Elizabethkingia meningoseptica bacteremia - experience from a level 1 trauma centre in India. Intractable Rare Dis Res. 2018;7:172–176.
George RM, Cochran CP, Wheeler WE. Epidemic meningitis of the newborn caused by flavobacteria. II. Clinical manifestations and treatment. Am J Dis Child. 1961;101:296–304.
Di Pentima MC, Mason EO, Kaplan SL. In vitro antibiotic synergy against Flavobacterium meningosepticum: implications for therapeutic options. Clin Infect Dis. 1998;26:1169–1176.
Fraser SL, Jorgensen JH. Reappraisal of the antimicrobial susceptibilities of Chryseobacterium and Flavobacterium species and methods for reliable susceptibility testing. Antimicrob Agents Chemother. 1997;41:2738–2741.
Kirby JT, Sader HS, Walsh TR, et al. Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001). J Clin Microbiol. 2004;42:445–448.
Aber RC, Wennersten C, Moellering RC. Antimicrobial susceptibility of Flavobacteria. Antimicrob Agents Chemother. 1978;14:483–487.
Johny M, Khuffash FA, Elhag KM. Antimicrobial treatment of Flavobacterium meningosepticum infection. Ann Trop Paediatr. 1983;3:125–128.
Abrahamsen TG, Finne PH, Lingaas E. Flavobacterium meningosepticum infections in a neonatal intensive care unit. Acta Paediatr Scand. 1989;78:51–55.
Burnard D, Gore L, Henderson A, et al. Comparative genomics and antimicrobial resistance profiling of Elizabethkingia isolates reveal nosocomial transmission and in vitro susceptibility to Fluoroquinolones, Tetracyclines, and trimethoprim-sulfamethoxazole. J Clin Microbiol. 2020;58:e00730–e00720.
Chang Y, Zhang D, Niu S, et al. MBLs, rather than efflux pumps, led to carbapenem resistance in fosfomycin and aztreonam/avibactam resistant Elizabethkingia anophelis. Infect Drug Resist. 2021;14:315–327.
Lin JN, Lai CH, Yang CH, et al. Clinical manifestations, molecular characteristics, antimicrobial susceptibility patterns and contributions of target gene mutation to fluoroquinolone resistance in Elizabethkingia anophelis. J Antimicrob Chemother. 2018;73:2497–2502.
Dooley JR, Nims LJ, Lipp VH, et al. Meningitis of infants caused by Flavobacterium meningosepticum: report of a patient and analysis of 63 infections. J Trop Pediatr. 1980;26:24–30.
Umair A, Nasir N. Clinical features and outcomes of critically ill patients with Elizabethkingia meningoseptica: an emerging pathogen. Acute Crit Care. 2021;36:256–261.
Güngör S, Ozen M, Akinci A, et al. A Chryseobacterium meningosepticum outbreak in a neonatal ward. Infect Control Hosp Epidemiol. 2003;24:613–617.